Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
GLUE
#2226
Monte Rosa Therapeutics, Inc. Common Stock
17.500
0
USD
-0.28%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
-0.28%
Changement Mensuel
+5.87%
Evolution sur 6 mois
+54.87%
Changement Annuel
+54.87%
Clôture Précédente
17.550
0
Open
17.500
0
Bid
Ask
Low
17.500
0
High
17.500
0
Volume
99
Marchés
Actions des Marchés US
Soins de Santé
GLUE
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
46.63 M
49.36 M
50.15 M
61.51 M
80.02 M
—
Valuation ratios
Enterprise value
606.12 M
329.1 M
158.28 M
202.62 M
1.12 B
1.81 B
Price to earnings ratio
—
-3.38
-2.17
-7.08
-34.09
36.44
Price to sales ratio
—
646.88
-576.57
6.78
10.53
18.09
Price to cash flow ratio
—
-3.97
-6.7
12.21
-57.13
-36.27
Price to book ratio
—
1.35
1.64
2.3
5.59
6.94
Enterprise value to EBITDA ratio
-8.55
-3.14
-1.17
-2.78
-25.94
18.87
Profitability ratios
Return on assets %
-0.2
-0.32
-0.45
-0.17
-0.09
-0.08
Return on equity %
-0.21
-0.4
-0.76
-0.33
-0.17
-0.18
Return on invested capital %
-843.49
-259.65
-266.73
-192.35
-149.4
-302.96
Gross margin %
100
100
100
100
100
400
Operating margin %
40.72 K
-19.79 K
28.16 K
-107.26
-43.83
-2 061.14
EBITDA margin %
39.63 K
-18.45 K
26.54 K
-96.52
-35.05
-1 859.83
Net margin %
41.32 K
-19.1 K
26.59 K
-96.14
-31.23
-1 868.84
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
20.96
10.79
5.07
2.4
6.12
25.43
Inventory turnover
—
—
—
—
—
—
Asset turnover
-0
0
-0
0.2
0.28
0.3
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-1.96
-0.85
0.57
-0.27
-0.27
EBIT per share
—
-2.37
-2.8
-1.1
-0.65
-0.66
EBITDA per share
—
-2.22
-2.63
-0.99
-0.52
-0.5
Total debt per share
—
—
—
—
—
—
Cash per share
—
1.16
2.49
3.03
4.54
13.77
Net current asset value per share
—
5.84
4.6
5.11
4.73
17.26
Tangible book value per share
—
5.75
3.49
3.02
2.81
12.37
Working capital per share
—
5.3
3.69
2.98
3.96
14.52
Book value per share
—
5.75
3.49
3.02
2.81
12.37
Nouvelles
Jefferies abaisse l’objectif de cours de Monte Rosa à 30$
Guggenheim abaisse l’objectif de cours de Monte Rosa à 30$
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Résultats de Monte Rosa Therapeutics attendus dans un contexte de baisse des revenus
Monte Rosa Therapeutics earnings on deck amid revenue decline
Dunn Edmund, directeur comptable, vend des actions Monte Rosa (GLUE) pour 2.496$
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
Les actions Monte Rosa progressent après les résultats d’essais sur le cancer de la prostate
Monte Rosa shares rise on prostate cancer trial results